Latest & greatest articles for tuberculosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tuberculosis

181. Diagnosis of Tuberculosis in Adults and Children

Diagnosis of Tuberculosis in Adults and Children Practice Guidelines Search Search Practice Guidelines Practice guidelines are systematically developed statements to assist practitioners and patients in making decisions about appropriate health care for specific clinical circumstances. Attributes of good guidelines include validity, reliability, reproducibility, clinical applicability, clinical flexibility, clarity, multidisciplinary process, review of evidence, and documentation. [Institute

2016 Infectious Diseases Society of America

182. Treatment of Drug-Susceptible Tuberculosis

Treatment of Drug-Susceptible Tuberculosis Practice Guidelines Search Search Practice Guidelines Practice guidelines are systematically developed statements to assist practitioners and patients in making decisions about appropriate health care for specific clinical circumstances. Attributes of good guidelines include validity, reliability, reproducibility, clinical applicability, clinical flexibility, clarity, multidisciplinary process, review of evidence, and documentation. [Institute

2016 Infectious Diseases Society of America

183. Imaging of Possible Tuberculosis

Imaging of Possible Tuberculosis American College of Radiology End User License Agreement ACR Appropriateness Criteria is a registered trademark of the American College of Radiology. By accessing the ACR Appropriateness Criteria®, you expressly agree and consent to the terms and conditions as described at: http://www.acr.org/~/media/ACR/Documents/AppCriteria/TermsandConditions.pdf Personal use of material is permitted for research, scientific and/or information purposes only. You may not modify (...) or create derivative works based on American College of Radiology material. No part of any material posted on the American College of Radiology Web site may be copied, downloaded, stored in a retrieval system, or redistributed for any other purpose without the expressed written permission of American College of Radiology. New 2016 ACR Appropriateness Criteria ® 1 Imaging of Possible Tuberculosis American College of Radiology ACR Appropriateness Criteria ® Imaging of Possible Tuberculosis Variant 1

2016 American College of Radiology

185. Latent Tuberculosis Infection: Screening

Latent Tuberculosis Infection: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Asymptomatic adults at increased risk for infection The USPSTF recommends screening for latent tuberculosis infection (LTBI) in populations at increased risk. B View the Clinical Summary in Population Asymptomatic adults at increased risk for infection Recommendation Screen for latent tuberculosis infection (LTBI). Grade: B Risk (...) Assessment Populations at increased risk for LTBI include persons who were born in, or are former residents of, countries with increased tuberculosis prevalence and persons who live in, or have lived in, high-risk congregate settings (eg, homeless shelters and correctional facilities). Local demographic patterns may vary across the United States; clinicians can consult their local or state health departments for more information about populations at risk in their community. Screening Tests Screening

2016 U.S. Preventive Services Task Force

186. Primary tuberculosis of palate Full Text available with Trip Pro

Primary tuberculosis of palate Primary tuberculosis (TB) of the hard palate is very rare. A 74-year-old man was presented with 6-month history of dysphagia along with an irregular mass in the hard and soft palate. Magnetic resonance imaging (MRI) revealed thickened and increased signal intensity within hard and soft palate. Tissue biopsy showed focal caseating granulomatous-like lesion and the histochemical staining using Ziehl-Neelsen stain for acid-fast bacilli was positive. Positive

2015 Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia

187. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. Full Text available with Trip Pro

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. 26649984 2015 12 18 2015 12 17 1533-4406 373 25 2015 Dec 17 The New England journal of medicine N. Engl. J. Med. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. e29 10.1056/NEJMx150041 eng Published Erratum 2015 12 09 United States N Engl J Med 0255562 0028-4793 N Engl J Med. 2015 Nov 12;373(20):1986-8 26559594 Stuckia, David [corrected to Stucki, David] 2015 12 10 6 0 2015 12 10 6 0 2015

2015 NEJM

188. Molecular docking studies on InhA, MabA and PanK enzymes from Mycobacterium tuberculosis of ellagic acid derivatives from Ludwigia adscendens and Trewia nudiflora Full Text available with Trip Pro

Molecular docking studies on InhA, MabA and PanK enzymes from Mycobacterium tuberculosis of ellagic acid derivatives from Ludwigia adscendens and Trewia nudiflora There is an urgent need to discover and develop new drugs to combat Mycobacterium tuberculosis, the causative agent of tuberculosis (TB) in humans. In recent years, there has been a renewed interest in the discovery of new anti-TB agents from natural sources. In the present investigation, molecular docking studies were carried out (...) on two ellagic acid derivatives, namely pteleoellagic acid (1) isolated from Ludwigia adscendens, and 3,3'-di-O-methyl ellagic acid 4-O-α-rhamnopyranoside (2) isolated from Trewia nudiflora, to investigate their binding to two enzymes involved in M. tuberculosis cell wall biogenesis, namely 2-trans-enoyl-ACP reductase (InhA) and β-ketoacyl-ACP reductase (MabA), and to pantothenate kinase (PanK type I) involved in the biosynthesis of coenzyme A, essential for the growth of M. tuberculosis.Molecular

2015 In silico pharmacology

189. Disseminated Tuberculosis in an Immunocompetent Patient: The Answer is in the Liver Full Text available with Trip Pro

Disseminated Tuberculosis in an Immunocompetent Patient: The Answer is in the Liver Tuberculosis, a chronic infectious disease caused by Mycobacterium tuberculosis, may invade all organs but mainly affect the lungs. We report a case of disseminated tuberculosis with hepatic, pericardial and pleural involvement and a review of the relevant literature. A 64-year-old Portuguese male was admitted with epigastric and right upper quadrant pain associated with low grade fever, fatigue, nausea (...) , anorexia, weight loss (6 kg) and mild jaundice. A chest X-ray showed cardiomegaly and a computed tomographic scan of the thorax and abdomen revealed a mild left pleural effusion, a thickened pericardium with signs of incipient calcification and hepatomegaly. The echocardiogram suggested the diagnosis of constrictive pericarditis. Liver biopsy revealed granulomatous lesions with central caseating necrosis. Tuberculosis is usually associated with atypical clinical manifestations. Imaging examination

2015 GE Portuguese journal of gastroenterology

190. Treatment of Tuberculosis. (Abstract)

Treatment of Tuberculosis. 26605929 2015 12 04 2016 11 26 1533-4406 373 22 2015 Nov 26 The New England journal of medicine N. Engl. J. Med. Treatment of Tuberculosis. 2149-60 10.1056/NEJMra1413919 Horsburgh C Robert CR Jr Barry Clifton E CE 3rd Lange Christoph C eng Journal Article Review United States N Engl J Med 0255562 0028-4793 0 Antitubercular Agents AIM IM Adult Antitubercular Agents pharmacokinetics therapeutic use Child Humans Lung diagnostic imaging Mycobacterium tuberculosis (...) physiology Tomography, X-Ray Computed Tuberculosis diagnostic imaging drug therapy 2015 11 26 6 0 2015 11 26 6 0 2015 12 15 6 0 ppublish 26605929 10.1056/NEJMra1413919

2015 NEJM

191. Data for action: collection and use of local data to end tuberculosis. Full Text available with Trip Pro

Data for action: collection and use of local data to end tuberculosis. Accelerating progress in the fight against tuberculosis will require a drastic shift from a strategy focused on control to one focused on elimination. Successful disease elimination campaigns are characterised by locally tailored responses that are informed by appropriate data. To develop such a response to tuberculosis, we suggest a three-step process that includes improved collection and use of existing programmatic data (...) , collection of additional data (eg, geographic information, drug resistance, and risk factors) to inform tailored responses, and targeted collection of novel data (eg, sequencing data, targeted surveys, and contact investigations) to improve understanding of tuberculosis transmission dynamics. Development of a locally targeted response for tuberculosis will require substantial investment to reconfigure existing systems, coupled with additional empirical data to evaluate the effectiveness of specific

2015 Lancet

192. Stopping tuberculosis: a biosocial model for sustainable development. Full Text available with Trip Pro

Stopping tuberculosis: a biosocial model for sustainable development. Tuberculosis transmission and progression are largely driven by social factors such as poor living conditions and poor nutrition. Increased standards of living and social approaches helped to decrease the burden of tuberculosis before the introduction of chemotherapy in the 1940s. Since then, management of tuberculosis has been largely biomedical. More funding for tuberculosis since 2000, coinciding with the Millennium (...) Development Goals, has yielded progress in tuberculosis mortality but smaller reductions in incidence, which continues to pose a risk to sustainable development, especially in poor and susceptible populations. These at-risk populations need accelerated progress to end tuberculosis as resolved by the World Health Assembly in 2015. Effectively addressing the worldwide tuberculosis burden will need not only enhancement of biomedical approaches but also rebuilding of the social approaches of the past

2015 Lancet

193. Latent Mycobacterium tuberculosis Infection. (Abstract)

Latent Mycobacterium tuberculosis Infection. 26376149 2015 09 17 2018 12 02 1533-4406 373 12 2015 09 17 The New England journal of medicine N. Engl. J. Med. Latent Mycobacterium tuberculosis Infection. 1179-80 10.1056/NEJMc1508223 Getahun Haileyesus H Chaisson Richard E RE Raviglione Mario M eng P30 AI094189 AI NIAID NIH HHS United States Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antitubercular Agents V83O1VOZ8L Isoniazid AIM IM N Engl J Med. 2015 May 28;372(22):2127-35 (...) 26017823 N Engl J Med. 2015 Sep 17;373(12):1178 26376150 N Engl J Med. 2015 Sep 17;373(12):1178 26376151 N Engl J Med. 2015 Sep 17;373(12):1178-9 26376152 N Engl J Med. 2015 Sep 17;373(12):1179 26376153 Antitubercular Agents administration & dosage Humans Isoniazid administration & dosage Latent Tuberculosis Mycobacterium tuberculosis 2015 9 17 6 0 2015 9 17 6 0 2015 9 18 6 0 ppublish 26376149 10.1056/NEJMc1508223 10.1056/NEJMc1508223#SA5

2015 NEJM

194. Latent Mycobacterium tuberculosis Infection. Full Text available with Trip Pro

Latent Mycobacterium tuberculosis Infection. 26376150 2015 09 17 2018 12 02 1533-4406 373 12 2015 09 17 The New England journal of medicine N. Engl. J. Med. Latent Mycobacterium tuberculosis Infection. 1178 10.1056/NEJMc1508223 Jones Jeffrey G JG King Thomas C TC eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antitubercular Agents V83O1VOZ8L Isoniazid AIM IM N Engl J Med. 2015 May 28;372(22):2127-35 26017823 N Engl J Med. 2015 Sep 17;373(12):1179-80 26376149 Antitubercular (...) Agents administration & dosage Humans Isoniazid administration & dosage Latent Tuberculosis Mycobacterium tuberculosis 2015 9 17 6 0 2015 9 17 6 0 2015 9 18 6 0 ppublish 26376150 10.1056/NEJMc1508223 10.1056/NEJMc1508223#SA1

2015 NEJM

195. Latent Mycobacterium tuberculosis Infection. Full Text available with Trip Pro

Latent Mycobacterium tuberculosis Infection. 26376151 2015 09 17 2018 12 02 1533-4406 373 12 2015 09 17 The New England journal of medicine N. Engl. J. Med. Latent Mycobacterium tuberculosis Infection. 1178 10.1056/NEJMc1508223 Ogbuagu Onyema O Ogbuagu Arit A eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antitubercular Agents V83O1VOZ8L Isoniazid AIM IM N Engl J Med. 2015 May 28;372(22):2127-35 26017823 N Engl J Med. 2015 Sep 17;373(12):1179-80 26376149 Antitubercular Agents (...) administration & dosage Humans Isoniazid administration & dosage Latent Tuberculosis Mycobacterium tuberculosis 2015 9 17 6 0 2015 9 17 6 0 2015 9 18 6 0 ppublish 26376151 10.1056/NEJMc1508223 10.1056/NEJMc1508223#SA2

2015 NEJM

196. Latent Mycobacterium tuberculosis Infection. Full Text available with Trip Pro

Latent Mycobacterium tuberculosis Infection. 26376152 2015 09 17 2018 12 02 1533-4406 373 12 2015 09 17 The New England journal of medicine N. Engl. J. Med. Latent Mycobacterium tuberculosis Infection. 1178-9 10.1056/NEJMc1508223 Tam John K C JK eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antitubercular Agents V83O1VOZ8L Isoniazid AIM IM N Engl J Med. 2015 May 28;372(22):2127-35 26017823 N Engl J Med. 2015 Sep 17;373(12):1179-80 26376149 Antitubercular Agents (...) administration & dosage Humans Isoniazid administration & dosage Latent Tuberculosis Mycobacterium tuberculosis 2015 9 17 6 0 2015 9 17 6 0 2015 9 18 6 0 ppublish 26376152 10.1056/NEJMc1508223 10.1056/NEJMc1508223#SA3

2015 NEJM

197. Latent Mycobacterium tuberculosis Infection. Full Text available with Trip Pro

Latent Mycobacterium tuberculosis Infection. 26376153 2015 09 17 2018 12 02 1533-4406 373 12 2015 09 17 The New England journal of medicine N. Engl. J. Med. Latent Mycobacterium tuberculosis Infection. 1179 10.1056/NEJMc1508223 Flood Jennifer J Scott James J Belknap Robert R eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antitubercular Agents V83O1VOZ8L Isoniazid AIM IM N Engl J Med. 2015 May 28;372(22):2127-35 26017823 N Engl J Med. 2015 Sep 17;373(12):1179-80 26376149 (...) Antitubercular Agents administration & dosage Humans Isoniazid administration & dosage Latent Tuberculosis Mycobacterium tuberculosis 2015 9 17 6 0 2015 9 17 6 0 2015 9 18 6 0 ppublish 26376153 10.1056/NEJMc1508223 10.1056/NEJMc1508223#SA4

2015 NEJM

198. Diagnostic Challenges in Latent Tuberculosis Infection: A Brief Review of Available Tests and their Appropriate Use

Diagnostic Challenges in Latent Tuberculosis Infection: A Brief Review of Available Tests and their Appropriate Use Diagnostic Challenges in Latent Tuberculosis Infection: A Brief Review of Available Tests and their Appropriate Use – Clinical Correlations Search Diagnostic Challenges in Latent Tuberculosis Infection: A Brief Review of Available Tests and their Appropriate Use July 15, 2015 14 min read By: Miguel A. Saldivar, MD Peer Reviewed “Indeterminate.” Many clinicians have expressed (...) frustration when reading this word on a Quantiferon-TB Gold test result. The obligate follow-up question is: what is the next best step? Repeat the Quantiferon? Ignore it altogether and perform a Tuberculin Skin Test (TST) instead? Even worse, what happens when both tests are performed with discordant results? In order to answer some of these questions, this article begins with a very brief overview of Mycobacterium tuberculosis (TB) infection epidemiology. This is followed by a review of the tools

2015 Clinical Correlations

199. Bedaquiline (Sirturo) - pulmonary multidrug resistant tuberculosis

Bedaquiline (Sirturo) - pulmonary multidrug resistant tuberculosis Final Appraisal Recommendation Advice No: 0815 – March 2015 Bedaquiline (Sirturo ® ? ) 100 mg tablets Submission by Janssen-Cilag Ltd Additional note(s): ? AWMSG considered that bedaquiline (Sirturo ® ? ) satisfies the AWMSG criteria for ultra-orphan drug status. In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1334), which includes (...) Recommendation of AWMSG Bedaquiline (Sirturo ® ? ) is recommended as an option for use within NHS Wales for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group. Final

2015 All Wales Medicines Strategy Group

200. Guidelines on the management of latent tuberculosis infection

Guidelines on the management of latent tuberculosis infection Guidelines on the management of latent tuberculosis infection© World Health Organization 2015 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce (...) Data Guidelines on the management of latent tuberculosis infection. 1.Latent Tuberculosis. 2.Immunologic T ests. 3.Mycobacterium Tuberculosis – immunology. 4.Antitubercular Agents. 5.Guideline. I.World Health Organization. ISBN 978 92 4 154890 8 (NLM classification: WF 200)Guidelines on the management of latent tuberculosis infection1 Guidelines on the management of latent tuberculosis infection Contents Acknowledgements 2 Abbreviations 5 Declaration and management of conflict of interest 6

2015 World Health Organisation Guidelines